Recent developments for ALX Oncology center on the clinical advancement of its lead therapeutic candidate, evorpacept, across multiple Phase 2 and Phase 3 trials evaluating combinations with standard-of-care treatments for solid tumors and hematologic malignancies. Financially, the company continues to manage its clinical trial expenditures through disciplined capital allocation, strategic public offerings, and research collaborations to sustain its drug development roadmap.